Ironwood Pharmaceuticals, Inc.IRWDNASDAQ
LOADING
|||
EPS Growth Under Pressure
Trending lower, above historical average.
Left:
||||
Year-over-year earnings per share growth rate
Latest
66.67%
↑ 197% above average
Average (39q)
-68.41%
Historical baseline
Range
High:868.00%
Low:-2380.00%
CAGR
-0.1%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 66.67% |
| Q2 2025 | 165.22% |
| Q1 2025 | -1731.21% |
| Q4 2024 | -38.16% |
| Q3 2024 | 522.22% |
| Q2 2024 | 79.55% |
| Q1 2024 | -164.00% |
| Q4 2023 | -110.17% |
| Q3 2023 | 101.44% |
| Q2 2023 | -2380.00% |
| Q1 2023 | -6.25% |
| Q4 2022 | 14.29% |
| Q3 2022 | 16.67% |
| Q2 2022 | 14.29% |
| Q1 2022 | -16.00% |
| Q4 2021 | -26.47% |
| Q3 2021 | -85.95% |
| Q2 2021 | 868.00% |
| Q1 2021 | -7.41% |
| Q4 2020 | 22.73% |
| Q3 2020 | 37.50% |
| Q2 2020 | 700.00% |
| Q1 2020 | -93.55% |
| Q4 2019 | 138.46% |
| Q3 2019 | 62.50% |
| Q2 2019 | 121.05% |
| Q1 2019 | -280.00% |
| Q4 2018 | 91.23% |
| Q3 2018 | -256.25% |
| Q2 2018 | -10.34% |
| Q1 2018 | -462.50% |
| Q4 2017 | 136.36% |
| Q3 2017 | 26.67% |
| Q2 2017 | 16.67% |
| Q1 2017 | -290.03% |
| Q4 2016 | 59.87% |
| Q3 2016 | -53.33% |
| Q2 2016 | -61.99% |
| Q1 2016 | 5.80% |
| Q4 2015 | 70.21% |